Research programme: glycan-binding biopharmaceuticals - ProtAffin Biotechnologie

Drug Profile

Research programme: glycan-binding biopharmaceuticals - ProtAffin Biotechnologie

Alternative Names: MCP-1 programme - ProtAffin; Oncology programme - ProtAffin; PA508; SDF-1α programme - ProtAffin

Latest Information Update: 04 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProtAffin Biotechnologie
  • Class Proteins
  • Mechanism of Action Glycosaminoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis; Diabetic retinopathy; Fibrosis; Multiple sclerosis; Myocardial infarction; Uveitis

Most Recent Events

  • 31 Jul 2013 ProtAffin Biotechnologie has ceased operations
  • 31 Jul 2013 Discontinued - Preclinical for Coronary artery restenosis in Austria (Parenteral)
  • 31 Jul 2013 Discontinued - Preclinical for Multiple sclerosis in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top